Drugs: USA
The question
To ask the Secretary of State for Health and Social Care, whether his Department has considered the potential merits of publishing an impact assessment for the US-UK Arrangement on Pharmaceuticals Pricing and Tariffs in which commercially sensitive material is redacted.
Answered by Department of Health and Social Care
The UK-US Arrangement on Pharmaceutical Pricing and Tariffs is intended to support National Health Service patients’ access to innovative medicines, while strengthening the United Kingdom’s life sciences sector. The terms of the arrangement have been published in full, and we have answered numerous questions about its operation in parliamentary questions and debate.
Publishing a redacted impact assessment would not aid understanding around the deal. The analysis depends on assumptions about future medicines approvals, NHS uptake, global pricing policies, and wider commercial discussions. Removing commercially sensitive material would remove much of the context needed to understand that analysis properly.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →